Susie M. Collins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susie M. Collins has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Clare Buckeridge
Pfizer Research and Development Cambridge Massachusetts USA
18 shared publications - Roberto A. Calle
GSK, Waltham, MA, USA; New York Medical College, Department of Medicine, Valhalla, NY, USA
18 shared publications - Shannon L. Lubaczewski
Early Clinical Development Biomedicine Artificial Intelligence, Pfizer Inc, Collegeville, Pennsylvania
18 shared publications - Anil Tarachandani
Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts
17 shared publications - Ellen Q. Wang
Clinical Pharmacology & Bioanalytics, Pfizer Inc. New York New York USA
17 shared publications - James H. Revkin
Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts
17 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Representativeness of Study Participants
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Representativeness of Study Participants
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of supplementary methods
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of serum unbound and total ponsegromab Ctrough
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of serum unbound and total ponsegromab Ctrough
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Median serum unbound and total ponsegromab and GDF-15 concentration–time profiles (semi-log scale)
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Median serum unbound and total ponsegromab and GDF-15 concentration–time profiles (semi-log scale)
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Median serum unbound and total ponsegromab and GDF-15 concentration–time profiles (semi-log scale)
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Median serum unbound and total ponsegromab and GDF-15 concentration–time profiles (semi-log scale)
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Summary of accelerometry-based monitoring of sedentary activity time (A), light activity time (B), moderate activity time (C), average activity level during the maximum 6 minutes of daily activity (D), total sleep time (E), and gait speed (F) at baseline, week 6 and week 12